Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

Summary

The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen. If the vaccine is therapeutically useful, a second goal is to establish the maximum therapeutic dose to treat patients with NY-ESO-1 positive cancers.

Timeline

Start

2011-05

Primary completion

2013-11

Completion

2014-03

Drugs

Indications